Cipla's consolidated revenue declined 2.4% to Rs 7,404 crore in Q2 FY27 as its North America and API businesses weakened, while India revenue grew 12% to Rs 3,516 crore. The pharmaceutical major reported revenue of Rs 7,404 crore for the September quarter, while EBITDA margin contracted to 18.7 per cent from 25 per cent a year.